Immuno oncology News and Research

RSS

Personalization techniques give a new lease of life to anticancer vaccines

Anticancer vaccines have gained a new lease of life with techniques to personalise them to individual patients.

19 Dec 2018

The EORTC Brain Tumor Group and Protagen AG collaborate to study immuno-competence of long-term glioblastoma survivors

The European Organisation for Research and Treatment of Cancer Brain Tumor Group and Protagen AG today announced a collaboration to utilize Protagen’s Cancer Immunotherapy Array to identify autoantibody biomarkers that investigate the immunological profile and immuno-competence of long-term Glioblastoma survivors.

12 Dec 2018

Integral Molecular and Merus collaborate to develop bispecific antibody therapeutics

Integral Molecular, the industry leader in the discovery of monoclonal antibodies against membrane proteins, and Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced that they have entered into a collaboration on multiple undisclosed targets.

12 Dec 2018

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

Innovation in immuno-oncology is exploding and new technologies that are set to benefit many patients with cancer are being showcased in the highly diverse array of topics to be discussed at the ESMO Immuno-Oncology Congress, to be held 13-16 December in Geneva, Switzerland.

11 Dec 2018

Customizing Genetically Engineered Models for Specific Research Applications

In this interview conducted at SfN 2018, Philip Dubé from Taconic Biosciences, goes into detail about genetically engineered models and their importance in understanding neurodegenerative diseases.

From Taconic Biosciences, Inc. 4 Dec 2018

Forming 3D Neuronal Models of the Brain

In this interview, conducted at SfN 2018, Grischa Chandy from Molecular Devices provides insight on 3D imaging solutions for neuroscience research.

From Molecular Devices, LLC 19 Nov 2018

Amgen announces presentation of new clinical data showcasing early oncology pipeline at ASH 2018

Amgen today announced that new clinical data will be presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, Dec. 1-4, 2018. Data across an array of malignancies will be featured in 45 abstracts, including nine oral presentations, from the Company’s broad portfolio andearly-stage pipeline.

From AMGEN 5 Nov 2018

Cytek Biosciences introduces new Northern Lights series of advanced flow cytometry systems

The door to discovery has been opened, and the traditional flow cytometry market is set to see a paradigm shift. With its new Northern Lights series of advanced flow cytometry systems, Cytek Biosciences Inc. is making three lasers and more than 24 colors possible at a price point typically attached to systems with far fewer capabilities.

From Cytek Biosciences 2 Nov 2018

Integral Molecular wins NIH grant to initiate target discovery program for Alzheimer’s disease

Integral Molecular, the industry leader in membrane protein technologies, was awarded a Small Business Innovation Research grant from the NIH to initiate a target discovery program for Alzheimer's disease.

1 Nov 2018

Newly developed synthetic DNA molecule may one day be used as 'vaccine' for prostate cancer

Researchers from City of Hope, a world-renowned comprehensive cancer center and independent biomedical research institution, have developed a synthetic DNA molecule that is programmed to jump-start the immune system to eradicate genetically distinct types of prostate cancer.

19 Oct 2018

LJI and UC San Diego awarded $ 4.5 million as part of NCI's Cancer Moonshot initiative

Researchers at La Jolla Institute for Immunology and UC San Diego have been awarded $ 4.5 million as part of the National Cancer Institute's Cancer Moonshot initiative.

19 Oct 2018

Themis, Max-Planck-Innovation sign license agreement to develop and commercialize oncolytic virotherapies

Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry. Financial terms of the agreement were not disclosed.

11 Oct 2018

HalioDx announces availability of Brightplex, a high capacity IHC multiplex technology

HalioDx, an immuno-oncology company pioneering the immunological diagnosis of cancers, announces the availability of Brightplex, a novel high capacity IHC multiplex technology enabling multiple biomarkers to be analyzed on a single FFPE slide.

4 Oct 2018

UCI researchers receive $3.4 million grant to study new class of cancer killing immunotherapeutics

UCI School of Medicine researchers have been awarded a $3.4 million grant by the National Cancer Institute as part of the Beau Biden Cancer Moonshot initiative.

27 Sep 2018

Cytek Biosciences completes Series C funding round

Cytek Biosciences Inc., the preeminent provider of innovative flow cytometry solutions, today announced the completion of a Series C funding round co-led by Northern Light Venture Capital and 3E Bioventures.

From Cytek Biosciences 27 Sep 2018

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a clinical-stage rare disease and oncology company focused on sourcing and developing innovative treatments for underserved patient populations, announced today that the companies have entered into a global clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene's investigational RAF dimer inhibitor, lifirafenib and SpringWorks Therapeutics' investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors.

6 Sep 2018

Insilico announces presentation of latest research at Global Precision Medicine & Biomarkers Leaders Summit

Insilico Medicine, a Rockville-based company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research, announces the presentation of its CTO, Alex Zhebrak at the 5th Global Precision Medicine & Biomarkers Leaders Summit, September 13-14, 2018, Munich, Germany.

27 Aug 2018

Bluebird bio collaborates with Gritstone Oncology to develop novel cancer cell therapies

Bluebird bio, Inc. and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.

23 Aug 2018

FDA approves Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma

Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma.

22 Aug 2018

Harbour Biomed and Kelun-Biotech collaborate to develop, commercialize anti-PD-L1 antibody

Harbour BioMed today announced it has entered into an exclusive strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize A167, an anti-PD-L1 antibody in Phase 2 clinical development, worldwide outside of the Greater China region.

20 Aug 2018